Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors

PURPOSE: M7824 (MSB0011359C) is an innovative first-in-class bifunctional fusion protein composed of a mAb against programmed death ligand 1 (PD-L1) fused to a TGFβ “trap.” EXPERIMENTAL DESIGN: In the 3+3 dose-escalation component of this phase I study (NCT02517398), eligible patients with advanced...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Strauss, Julius, Heery, Christopher R., Schlom, Jeffrey, Madan, Ravi A., Cao, Liang, Kang, Zhigang, Lamping, Elizabeth, Marté, Jennifer L., Donahue, Renee N., Grenga, Italia, Cordes, Lisa, Christensen, Olaf, Mahnke, Lisa, Helwig, Christoph, Gulley, James L.
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7985967/
https://ncbi.nlm.nih.gov/pubmed/29298798
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-2653
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados